Paloma Partners Management Co acquired a new position in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,900 shares of the company’s stock, valued at approximately $58,000. Paloma Partners Management Co owned about 0.05% of Corvus Pharmaceuticals as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter worth approximately $107,000. Rhumbline Advisers increased its position in shares of Corvus Pharmaceuticals by 44.1% during the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock valued at $67,000 after acquiring an additional 5,570 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $182,000. Prudential Financial Inc. increased its position in shares of Corvus Pharmaceuticals by 15.0% during the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock valued at $79,000 after acquiring an additional 2,805 shares during the last quarter. Finally, Credit Suisse AG purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $194,000. 85.71% of the stock is owned by hedge funds and other institutional investors.
Shares of CRVS opened at $4.00 on Tuesday. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.
CRVS has been the subject of a number of research analyst reports. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Monday, January 14th. ValuEngine downgraded Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Wedbush decreased their price target on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $11.94.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Read More: QQQ ETF
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.